Results 1 to 10 of about 138,714 (357)
Protective Activities of Growth Hormone-Releasing Hormone Antagonists against Toxin-Induced Endothelial Injury [PDF]
EndocrinesGHRH regulates the secretion of GH from the anterior pituitary gland, previously associated with cancer progression and inflammation. An emerging body of evidence suggests that GHRHAnt support endothelial barrier function, but the mechanisms mediating ...
Saikat Fakir, Nektarios Barabutis
doaj +2 more sources
Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Endometriosis: Advances in Research. [PDF]
J Clin Med ResWang JY, Zhang Y, Ding J.
europepmc +3 more sources
Differential Changes in Expression of Stress- and Metabolic-related Neuropeptides in the Rat Hypothalamus during Morphine Dependence and Withdrawal [PDF]
, 2013 Chronic morphine treatment and naloxone precipitated morphine withdrawal activates stress-related brain circuit and results in significant changes in food intake, body weight gain and energy metabolism.
Ferenczi, Szilamér +6 more
core +13 more sources
Neural Regeneration Research, 2022 Both inflammation and anti-inflammation are involved in the protection of retinal cells. Antagonists of the hypothalamic growth hormone-releasing hormone receptor (GHRHR) have been shown to possess potent anti-inflammatory properties in experimental ...
Ling-Ping Cen +3 more
doaj +1 more source
Luteinizing hormone-releasing hormone antagonists [PDF]
Expert Opinion on Therapeutic Patents, 2009 Luteinizing hormone-releasing hormone (LH-RH) plays a central role in the vertebrate reproduction by regulating gonadal activity. Based on its binding to pituitary LH-RH receptors, as well as to LH-RH receptors expressed on cancer cells, LH-RH agonists and antagonists have been developed for different therapeutic applications.Here we give an overview ...
Mezö, Gábor, Manea, Marilena
openaire +3 more sources
Androgen deprivation therapy and side effects: are GnRH antagonists safer?
Asian Journal of Andrology, 2021 Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists and antagonists is the mainstay of advanced prostate cancer treatment. Both drug classes decrease levels of luteinizing hormone and follicle-stimulating hormones (FSH),
Stephen J Freedland +1 more
doaj +1 more source
Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer
Société Internationale d’Urologie Journal, 2022 PurposeSubstantial evidence indicates that men with prostate cancer are at an increased risk for cardiovascular disease, and medical and surgical androgen deprivation therapy is associated with further increased cardiovascular risk. There are conflicting
Laurence Klotz +3 more
doaj +1 more source
F&S Reports, 2023 Gonadotropin-releasing hormone (GnRH) is central to the control of the entire hypothalamic-pituitary-gonadal axis. Manipulation of GnRH, in turn, regulates pituitary response and ovarian hormone production.
Farrah L. Saleh, M.D. +1 more
doaj +1 more source
Growth Hormone Receptor Antagonists [PDF]
The Journal of Clinical Endocrinology & Metabolism, 2004 Pegvisomant is the only member of a new class of drugs that was especially designed to block the GH receptor (GHR) and, therefore, GH action. In this review we will describe the structure and function of GH and its receptor with specific relevance to the discovery and development of GHR antagonists.
Müller, A.F. +3 more
openaire +2 more sources
Recent Development of Non-Peptide GnRH Antagonists
Molecules, 2017 The decapeptide gonadotropin-releasing hormone, also referred to as luteinizing hormone-releasing hormone with the sequence (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) plays an important role in regulating the reproductive system.
Feng-Ling Tukun +5 more
doaj +1 more source